346 related articles for article (PubMed ID: 15950288)
21. Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and compatative in vitro activity of the ketolide, telithromycin.
Felmingham D; Reinert RR; Hirakata Y; Rodloff A
J Antimicrob Chemother; 2002 Sep; 50 Suppl S1():25-37. PubMed ID: 12239226
[TBL] [Abstract][Full Text] [Related]
22. High prevalence of the ermB gene among erythromycin-resistant streptococcus pneumoniae isolates in Germany during the winter of 2000-2001 and in vitro activity of telithromycin.
Kresken M; Henrichfreise B; Bagel S; Brauers J; Wiedemann B
Antimicrob Agents Chemother; 2004 Aug; 48(8):3193-5. PubMed ID: 15273149
[TBL] [Abstract][Full Text] [Related]
23. Streptococcus pneumoniae and Streptococcus pyogenes isolated from a paediatric population in Great Britain and Ireland: the in vitro activity of telithromcycin versus comparators.
Shackcloth J; Williams L; Farrell DJ
J Infect; 2004 Apr; 48(3):229-35. PubMed ID: 15001301
[TBL] [Abstract][Full Text] [Related]
24. Regional trends in beta-lactam, macrolide, fluoroquinolone and telithromycin resistance among Streptococcus pneumoniae isolates 2001-2004.
Felmingham D; Cantón R; Jenkins SG
J Infect; 2007 Aug; 55(2):111-8. PubMed ID: 17568680
[TBL] [Abstract][Full Text] [Related]
25. Comparative in vitro activity of telithromycin against macrolide-resistant and -susceptible Streptococcus pneumoniae, Moraxella catarrhalis and Haemophilus influenzae.
Walsh F; Carnegy F; Willcock J; Amyes S
J Antimicrob Chemother; 2004 May; 53(5):793-6. PubMed ID: 15056640
[TBL] [Abstract][Full Text] [Related]
26. Characterization of erythromycin-resistant Streptococcus pneumoniae in Korea, and In Vitro activity of telithromycin against erythromycin-resistant Streptococcus pneumoniae.
Kim NJ; Park SJ; Choi SH; Lee MS; Choo EJ; Kwak YG; Woo JH; Ryu J; Jeong JY; Kim YS
Microb Drug Resist; 2005; 11(3):260-5. PubMed ID: 16201929
[TBL] [Abstract][Full Text] [Related]
27. mef(A) is the predominant macrolide resistance determinant in Streptococcus pneumoniae and Streptococcus pyogenes in Germany.
Bley C; van der Linden M; Reinert RR
Int J Antimicrob Agents; 2011 May; 37(5):425-31. PubMed ID: 21419605
[TBL] [Abstract][Full Text] [Related]
28. Distribution of macrolide resistance genes erm(B) and mef(A) among 160 penicillin-intermediate clinical isolates of Streptococcus pneumoniae isolated in southern France.
Marchandin H; Jean-Pierre H; Jumas-Bilak E; Isson L; Drouillard B; Darbas H; Carrière C
Pathol Biol (Paris); 2001 Sep; 49(7):522-7. PubMed ID: 11642013
[TBL] [Abstract][Full Text] [Related]
29. Molecular resistance mechanisms of macrolide-resistant invasive Streptococcus pneumoniae isolates from Alaska, 1986 to 2010.
Rudolph K; Bulkow L; Bruce M; Zulz T; Reasonover A; Harker-Jones M; Hurlburt D; Hennessy T
Antimicrob Agents Chemother; 2013 Nov; 57(11):5415-22. PubMed ID: 23959308
[TBL] [Abstract][Full Text] [Related]
30. Increased antimicrobial resistance among nonvaccine serotypes of Streptococcus pneumoniae in the pediatric population after the introduction of 7-valent pneumococcal vaccine in the United States.
Farrell DJ; Klugman KP; Pichichero M
Pediatr Infect Dis J; 2007 Feb; 26(2):123-8. PubMed ID: 17259873
[TBL] [Abstract][Full Text] [Related]
31. Molecular characterization of macrolide resistance mechanisms among Streptococcus pneumoniae and Streptococcus pyogenes isolated from the PROTEKT 1999-2000 study.
Farrell DJ; Morrissey I; Bakker S; Felmingham D
J Antimicrob Chemother; 2002 Sep; 50 Suppl S1():39-47. PubMed ID: 12239227
[TBL] [Abstract][Full Text] [Related]
32. [In vitro susceptibility of respiratory isolates of Streptococcus pneumoniae and Streptococcus pyogenes to telithromycin and 11 other antimicrobial agents: Turkish results of e-BASKETT-II surveillance study].
Gür D; Mülazimoğlu L; Unal S;
Mikrobiyol Bul; 2007 Jan; 41(1):1-9. PubMed ID: 17427547
[TBL] [Abstract][Full Text] [Related]
33. Comparative in vitro activity of telithromycin and beta-lactam antimicrobials against community-acquired bacterial respiratory tract pathogens in the United States: findings from the PROTEKT US study, 2000-2001.
Stratton CW; Brown SD
Clin Ther; 2004 Apr; 26(4):522-30. PubMed ID: 15189749
[TBL] [Abstract][Full Text] [Related]
34. Drug Resistance Characteristics and Macrolide-Resistant Mechanisms of Streptococcus pneumoniae in Wenzhou City, China.
Hu D; Sun Z; Luo X; Liu S; Yu L; Qu Y; Yang J; Yu J; Li X; Zhang J
Med Sci Monit; 2016 Aug; 22():2731-5. PubMed ID: 27483416
[TBL] [Abstract][Full Text] [Related]
35. High-level telithromycin resistance in laboratory-generated mutants of Streptococcus pneumoniae.
Walsh F; Willcock J; Amyes S
J Antimicrob Chemother; 2003 Sep; 52(3):345-53. PubMed ID: 12917252
[TBL] [Abstract][Full Text] [Related]
36. Macrolide resistance determinants in erythromycin-resistant Streptococcus pneumoniae in Turkey.
Gulay Z; Ozbek OA; Bicmen M; Gur D
Jpn J Infect Dis; 2008 Nov; 61(6):490-3. PubMed ID: 19050364
[TBL] [Abstract][Full Text] [Related]
37. Prevalence and macrolide resistance phenotypes and genotypes among clinical isolates of Streptococcus pneumoniae collected in Sofia, Bulgaria from 2001 to 2005.
Setchanova LP; Ouzounova-Raykova V; Zhelezova GZ; Mitov IG
J Chemother; 2007 Jun; 19(3):256-62. PubMed ID: 17594919
[TBL] [Abstract][Full Text] [Related]
38. Pharmacodynamic activity of telithromycin against macrolide-susceptible and macrolide-resistant Streptococcus pneumoniae simulating clinically achievable free serum and epithelial lining fluid concentrations.
Zhanel GG; Johanson C; Hisanaga T; Mendoza C; Laing N; Noreddin A; Wierzbowski A; Hoban DJ
J Antimicrob Chemother; 2004 Dec; 54(6):1072-7. PubMed ID: 15531596
[TBL] [Abstract][Full Text] [Related]
39. Susceptibility of Streptococcus pneumoniae to penicillin, azithromycin and telithromycin (PROTEKT 1999-2003).
Schito GC; Felmingham D
Int J Antimicrob Agents; 2005 Dec; 26(6):479-85. PubMed ID: 16289710
[TBL] [Abstract][Full Text] [Related]
40. Antimicrobial susceptibility of Streptococcus pneumoniae, Streptococcus pyogenes and Haemophilus influenzae collected from patients across the USA, in 2001-2002, as part of the PROTEKT US study.
Brown SD; Rybak MJ
J Antimicrob Chemother; 2004 Aug; 54 Suppl 1():i7-15. PubMed ID: 15265831
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
